REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 202 filers reported holding REATA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.43 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $151,560,175 | +11.5% | 1,486,467 | -0.6% | 0.08% | +6.6% |
| Q1 2023 | $135,914,217 | +139.7% | 1,494,877 | +0.2% | 0.08% | +130.3% |
| Q4 2022 | $56,690,121 | +121.3% | 1,492,238 | +46.4% | 0.03% | +120.0% |
| Q3 2022 | $25,620,000 | +33.6% | 1,019,512 | +61.6% | 0.02% | +36.4% |
| Q2 2022 | $19,172,000 | -7.5% | 630,873 | -0.3% | 0.01% | +10.0% |
| Q1 2022 | $20,729,000 | +21.0% | 632,758 | -2.6% | 0.01% | +25.0% |
| Q4 2021 | $17,132,000 | -73.8% | 649,654 | +0.1% | 0.01% | -74.2% |
| Q3 2021 | $65,310,000 | -28.5% | 649,147 | +0.6% | 0.03% | -29.5% |
| Q2 2021 | $91,326,000 | +50.8% | 645,280 | +6.2% | 0.04% | +33.3% |
| Q1 2021 | $60,569,000 | +46.4% | 607,503 | +81.6% | 0.03% | +32.0% |
| Q4 2020 | $41,362,000 | +32.0% | 334,578 | +4.0% | 0.02% | +13.6% |
| Q3 2020 | $31,340,000 | -32.2% | 321,701 | +8.6% | 0.02% | -37.1% |
| Q2 2020 | $46,211,000 | +22.7% | 296,188 | +13.5% | 0.04% | +2.9% |
| Q1 2020 | $37,663,000 | -36.8% | 260,924 | -10.5% | 0.03% | -12.8% |
| Q4 2019 | $59,566,000 | +970.8% | 291,388 | +320.4% | 0.04% | +875.0% |
| Q3 2019 | $5,563,000 | -3.3% | 69,305 | +13.7% | 0.00% | +33.3% |
| Q2 2019 | $5,751,000 | -8.8% | 60,974 | -17.4% | 0.00% | -25.0% |
| Q1 2019 | $6,305,000 | -34.4% | 73,811 | -56.9% | 0.00% | -42.9% |
| Q4 2018 | $9,611,000 | -50.8% | 171,372 | -28.3% | 0.01% | +16.7% |
| Q3 2018 | $19,538,000 | +728.2% | 238,992 | +254.1% | 0.01% | +500.0% |
| Q2 2018 | $2,359,000 | +530.7% | 67,495 | +268.9% | 0.00% | – |
| Q1 2018 | $374,000 | -47.8% | 18,297 | -27.8% | 0.00% | – |
| Q4 2017 | $717,000 | +125.5% | 25,349 | +146.6% | 0.00% | – |
| Q3 2017 | $318,000 | -71.0% | 10,280 | -70.3% | 0.00% | -100.0% |
| Q2 2017 | $1,096,000 | +621.1% | 34,671 | +414.0% | 0.00% | – |
| Q1 2017 | $152,000 | +117.1% | 6,745 | +108.5% | 0.00% | – |
| Q4 2016 | $70,000 | +191.7% | 3,235 | +246.0% | 0.00% | – |
| Q3 2016 | $24,000 | -79.7% | 935 | -84.4% | 0.00% | – |
| Q2 2016 | $118,000 | – | 5,992 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |